Skip to main
TMDX

TMDX Stock Forecast & Price Target

TMDX Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

TransMedics Group Inc. has shown a strong performance with a 7% increase in after-market shares following robust Q4 results and positive revenue guidance, accompanied by an improved operating margin forecast of over 16%. The company is positioned for growth through new product launches, accelerated adoption in heart and lung transplants, and significant international expansion, all of which contribute to a positive financial outlook. Additionally, ongoing adoption of the Organ Care System and improvements in organ utilization underscore the potential for TransMedics to establish a new standard of care in organ transplantation, enhancing value creation in the years ahead.

Bears say

TransMedics Group Inc. is facing a negative outlook primarily due to a projected decline of 250 basis points in operating margins resulting from heavy investments in its clinical pipeline and international infrastructure. Although the company reported year-over-year revenue growth in both product and service segments, key metrics such as gross margins at 58.1% fell short of targets and signaled underlying financial weakness. Additionally, risks surrounding product adoption, increased competition, potential reimbursement changes, and complexities in clinical trials further contribute to uncertainty regarding the company’s future revenue trajectory and market position.

TMDX has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Transmedics Group Inc (TMDX) Forecast

Analysts have given TMDX a Buy based on their latest research and market trends.

According to 9 analysts, TMDX has a Buy consensus rating as of Mar 31, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $154, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $154, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Transmedics Group Inc (TMDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.